Brown University School of Public Health, Providence, Rhode Island.
Rhode Island Department of Health, Providence.
JAMA Netw Open. 2022 Jul 1;5(7):e2223917. doi: 10.1001/jamanetworkopen.2022.23917.
The benefit of vaccination for preventing reinfection among individuals who have been previously infected with SARS-CoV-2 is largely unknown.
To obtain population-based estimates of the probability of SARS-CoV-2 reinfection and the effectiveness associated with vaccination after recovery from COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used Rhode Island statewide surveillance data from March 1, 2020, to December 9, 2021, on COVID-19 vaccinations, laboratory-confirmed cases, hospitalizations, and fatalities to conduct a population-based, retrospective study during periods when wild type, Alpha, and Delta strains of SARS-CoV-2 were predominant. Participants included Rhode Island residents aged 12 years and older who were previously diagnosed with COVID-19 and unvaccinated at the time of first infection, stratified into 3 subpopulations: long-term congregate care (LTCC) residents, LTCC employees, and the general population (ie, individuals not associated with congregate settings). Data were analyzed from October 2021 to January 2022.
Completion of the primary vaccination series, defined as 14 days after the second dose of an mRNA vaccine or 1 dose of vector virus vaccine.
The main outcome was SARS-CoV-2 reinfection, defined as a laboratory-confirmed positive result on a polymerase chain reaction (PCR) or antigen test at least 90 days after the first laboratory-confirmed positive result on a PCR or antigen test.
Overall, 3124 LTCC residents (median [IQR] age, 81 [71-89]; 1675 [53.6%] females), 2877 LTCC employees (median [IQR] age, 41 [30-53]; 2186 [76.0%] females), and 94 516 members of the general population (median [IQR] age, 35 [24-52] years; 45 030 [47.6%] females) met eligibility criteria. Probability of reinfection at 9 months for those who remained unvaccinated after recovery from prior COVID-19 was 13.0% (95% CI, 12.0%-14.0%) among LTCC residents, 10.0% (95% CI, 8.8%-11.5%) among LTCC employees, and 1.9% (95% CI, 1.8%-2.0%) among the general population. Completion of the primary vaccination series after infection was associated with 49% (95% CI, 27%-65%) protection among LTCC residents, 47% (95% CI, 19%-65%) protection among LTCC employees, and 62% (95% CI, 56%-68%) protection in the general population against reinfection, adjusting for potential sociodemographic and clinical confounders and temporal variation in infection rates.
These findings suggest that risk of SARS-CoV-2 reinfection after recovery from COVID-19 was relatively high among individuals who remained unvaccinated. Vaccination after recovery from COVID-19 was associated with reducing risk of reinfection by approximately half.
重要性:先前感染过 SARS-CoV-2 的个体接种疫苗对预防再感染的益处尚不清楚。
目的:获得基于人群的 SARS-CoV-2 再感染概率以及 COVID-19 康复后接种疫苗的有效性的估计值。
设计、地点和参与者:这项队列研究使用了 2020 年 3 月 1 日至 2021 年 12 月 9 日罗德岛州全州范围内的 COVID-19 疫苗接种、实验室确诊病例、住院和死亡监测数据,在野生型、Alpha 和 Delta 变异株 SARS-CoV-2 占主导地位的时期,进行了一项基于人群的回顾性研究。参与者包括罗德岛州年龄在 12 岁及以上、首次感染时未接种疫苗且未接种疫苗的 COVID-19 既往感染者,分为 3 个亚组:长期集体护理(LTCC)居民、LTCC 员工和一般人群(即与集体场所无关的个体)。数据分析于 2021 年 10 月至 2022 年 1 月进行。
暴露:完成初级疫苗接种系列,定义为接受 mRNA 疫苗第 2 剂后 14 天或接受载体病毒疫苗后 1 剂。
主要结果和措施:主要结果是 SARS-CoV-2 再感染,定义为在首次实验室确认的 PCR 或抗原检测阳性结果后至少 90 天,PCR 或抗原检测的实验室确认阳性结果再次出现。
结果:共有 3124 名 LTCC 居民(中位数[IQR]年龄,81 [71-89];1675 [53.6%]为女性)、2877 名 LTCC 员工(中位数[IQR]年龄,41 [30-53];2186 [76.0%]为女性)和 94516 名一般人群(中位数[IQR]年龄,35 [24-52]岁;45030 [47.6%]为女性)符合入选标准。在 COVID-19 康复后仍未接种疫苗的人群中,9 个月时再感染的概率为 LTCC 居民 13.0%(95%CI,12.0%-14.0%),LTCC 员工 10.0%(95%CI,8.8%-11.5%),一般人群 1.9%(95%CI,1.8%-2.0%)。在感染后完成初级疫苗接种系列与 LTCC 居民 49%(95%CI,27%-65%)、LTCC 员工 47%(95%CI,19%-65%)和一般人群 62%(95%CI,56%-68%)对再感染的保护作用相关,调整了潜在的社会人口统计学和临床混杂因素以及感染率的时间变化。
结论和相关性:这些发现表明,COVID-19 康复后未接种疫苗的个体再次感染 SARS-CoV-2 的风险相对较高。COVID-19 康复后接种疫苗与降低再感染风险约一半有关。